BriaCell Therapeutics Corp. (BCTX) Research

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.

Market snapshot

Symbol
BCTX
Price
$2.90
Day change
+3.57%
Market cap
$5.5M
P/E ratio
-0.69x
52-week range
2.6-31.6
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Allarity Therapeutics, Inc. (ALLR)
  • Aspire Biopharma Holdings, Inc. (ASBP)
  • Curis, Inc. (CRIS)
  • Citius Pharmaceuticals, Inc. (CTXR)
  • Entero Therapeutics, Inc. (ENTO)
  • Hoth Therapeutics, Inc. (HOTH)
  • Leap Therapeutics, Inc. (LPTX)
  • Moleculin Biotech, Inc. (MBRX)

Recent insider activity

  • Lustig Marc — P-Purchase (902935 shares) on 2024-05-14
  • Lustig Marc — P-Purchase (902935 shares) on 2024-05-14
  • Bondarenko Jamieson — P-Purchase (28000 shares) on 2022-12-28
  • Williams William V. — P-Purchase (2530 shares) on 2022-12-23
  • Bondarenko Jamieson — P-Purchase (22000 shares) on 2022-12-20

Open BriaCell Therapeutics Corp. (BCTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.